News

VERAXA Biotech raises $27.5M debt and $50M equity line ahead of Nasdaq listing through SPAC merger with Voyager Acquisition...

BioXcel's IGALMI demonstrates sustained benefit in at-home agitation trial, with efficacy maintained across repeated dosing over 12 weeks.

ViCentra triples insulin pump production capacity through Phillips Medisize partnership, enabling expansion into German and European markets.

Zenas BioPharma files for FDA approval for obexelimab in IgG4-related disease, showing 56% reduction in flare risk in Phase...

Pacira BioSciences defends board seats against activist challenge while posting record $726.4M revenue and advancing its diversified pipeline strategy.

ViCentra triples insulin pump manufacturing capacity to 17,000 users, positioning for European market expansion and U.S. entry.

Leica Biosystems and CellCarta expand companion diagnostic development globally using a parallel-execution model built and tested in China.

BXCL501 reduces agitation across severity levels in at-home trial, with strongest effects in severe cases ahead of FDA decision.

Zenas BioPharma files FDA application for obexelimab in IgG4-Related Disease, showing 56% flare risk reduction in Phase 3 trials.

Pacira BioSciences faces proxy fight over board seats at June meeting as activist pushes for change amid valuation concerns.